Surgical removal followed by targeted radiation therapy for neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase IV trial evaluates the effectiveness of combining surgical debulking with peptide receptor radionuclide therapy (PRRT) using lutetium Lu 177 dotatate in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors that have metastasized to the liver. Patients will undergo surgery to remove as much of the tumor as possible, followed by intravenous administration of the radioactive drug within 90 days. The study aims to measure the objective response rate, assess safety and tolerability, and analyze the tumor's genomic and radiomic profiles. Imaging studies will be conducted throughout the trial to monitor progress.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed and dated written informed consent
* Male or female \>= 18 years of age on the day of signing informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* Histologically confirmed well-differentiated gastrointestinal or pancreatic neuroendocrine tumor that is grade 1 or grade 2 (Ki-67 =\< 20%)
* Somatostatin receptor avidity of known or suspected neuroendocrine tumor (NET) lesion(s) assessed by a baseline copper-64 dotatate PET/CT scan performed within 6 months (180 days) prior to surgical debulking on study day 0. The somatostatin receptor avidity of the majority of suspected NET lesion(s) must be \>= normal liver uptake
* Patient must have hepatic metastasis or hepatic metastases. Provided required hepatic metastatic disease is present, patient can also have any other site or sites of metastatic disease
* White blood cell count (WBC) \>= 2000/uL (resulted =\< 90 days prior to surgical debulking on day 0 of participation in this study)
* Platelets \>= 75,000/uL (resulted =\< 90 days prior to surgical debulking on day 0 of participation in this study)
* Hemoglobin \>= 8.0 g/dL (resulted =\< 90 days prior to surgical debulking on day 0 of participation in this study)
* Creatinine clearance (CrCl) \>= 30 mL/minute (as calculated by the Cockcroft-Gault Formula with estimated creatinine clearance rate \[eCCR\] \>= 30 mL/min required for eligibility inclusion; or calculated/measured by an alternative established institutional standard consistently applied across participants at the site) (resulted =\< 90 days prior to surgical debulking on day 0 of participation in this study)
* Total bilirubin =\< 3.0 times institutional upper limit of normal (ULN) (resulted =\< 90 days prior to surgical debulking on day 0 of participation in this study)
* Serum albumin \>= 3.0 g/dL unless the prothrombin time is within normal range (resulted =\< 90 days prior to surgical debulking on day 0 of participation in this study)
* Women must not be breastfeeding and further agree to not breastfeed during treatment with lutetium Lu 177 dotatate; and for at least 2.5 months after patient's final dose of lutetium Lu 177 dotatate
* A woman of childbearing potential (WOCBP) - must have a negative serum or urine pregnancy test resulted within 28 days prior to initiation of first dose of lutetium Lu 177 dotatate on cycle 1, day 1; and must agree to follow instructions for using acceptable contraception from the time of signing consent, and until 7 months after her final dose of lutetium Lu 177 dotatate
* A man able to father children who is sexually active with a WOCBP must agree to follow instructions for using acceptable contraception, from the time of signing consent, and until 4 months after his final dose of lutetium Lu 177 dotatate

Exclusion Criteria:

* Patient has any tumor \> 3 cm deemed to be inoperable
* Patient has disease which is considered to be completely surgically resectable
* Patient has grade 3 neuroendocrine neoplasm (well-differentiated or poorly-differentiated tumor)
* Prior receipt of peptide receptor radionuclide therapy (PRRT)
* Patient possesses untreated or growing brain metastases (growth within 90 days prior to surgical debulking on day 0 of participation in this study)
* Unstable angina, congestive heart failure with New York Heart Association (NYHA) functional classification III or IV, or uncontrolled symptomatic cardiac arrythmia
* Any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which in the judgment of the patient's study physician may reasonably be expected to interfere with patient's completion of the study

Where it's running

• Vanderbilt University/Ingram Cancer Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Kamran Idrees, MD — Vanderbilt University/Ingram Cancer Center
• Study coordinator: Vanderbilt-Ingram Services for Timely Access
• Email: cip@vumc.org
• Phone: 800-811-8480

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Local treatment for liver metastases in colorectal cancer patients

  This study tests if combining local treatment for liver tumors with regular cancer therapy can help people with colorectal cancer live longer and feel better.

  Recruiting at 6 sites Anhui Provincial Hospital · Chuzhou, Anhui and 5 other locations · NCT06449937

• Testing pump chemotherapy for liver metastases from colorectal cancer

  This study is testing if adding a special type of chemotherapy delivered directly to the liver can help people with colorectal cancer that has spread to the liver live longer and have fewer problems compared to standard chemotherapy alone.

  Recruiting at 54 sites Phase 3 Eastern Cooperative Oncology Group · Birmingham, Alabama and 61 other locations · NCT05863195

• Using chemotherapy after surgery for high-risk pancreatic neuroendocrine tumors

  This study tests if a combination of two chemotherapy drugs can help prevent cancer from coming back in people who have had surgery for high-risk pancreatic neuroendocrine tumors.

  Recruiting at 381 sites Phase 2 SWOG Cancer Research Network · Anchorage, Alaska and 447 other locations · NCT05040360

• Combining NBTXR3 with radiation and immunotherapy for advanced solid tumors

  This study is testing a new treatment using NBTXR3 along with radiation and immunotherapy to see if it helps people with advanced solid tumors that have spread to the lungs or liver.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05039632

• Comparing short stitch and traditional suture techniques after liver surgery

  This study is testing whether a new short stitch method for closing the abdomen after liver surgery can help prevent hernias better than the traditional suture technique.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04982653

• New imaging technique to evaluate treatment response in colorectal cancer that has spread to the liver

  This study is testing a new imaging method to see if it can help doctors tell how well chemotherapy is working for people with colorectal cancer that has spread to the liver.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT04796818

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.